PRETTYBROOK - Key Persons
Job Titles:
- Managing Partner
- Managing Partner of Prettybrook Partners LLC
Ms. Enright currently serves as a Managing Partner of Prettybrook Partners LLC, a family office dedicated to investing in healthcare companies. Prettybrook has approximately 20 active investments in a variety of companies, typically as a co-investor with institutional private equity. She is a member of the Board and Chair of the Audit Committee of Amarin Corporation Plc (NASDAQ: AMRN); serves as the Chairman of the Board, Chair of the Nominating and Governance Committee and member of the Audit Committee and Compensation Committee of Dynatronics Corporation (NASDAQ: DYNT); is a member of the Board of Directors and Chair of the Governance, Nominating and Compensation Committee of Medical Facilities Corporation (TSX: DR); and is a member of the Board and Chair of the Audit Committee of Keystone Dental, Inc., a private company controlled by the private equity firm Accelmed. Previously, she served on the Board of Directors and the Chair of the Audit Committee of Brooklyn ImmunoTherapeutics, Inc (NASDAQ: BTX) during 2022; the Board of Directors and the Audit Committee of Biolase, Inc. (NASDAQ: BIOL) during 2013; was a member of the Board of Directors of Tigerlabs, a Princeton-based business accelerator, from 2012 to 2018; and from 2010 to 2015 served on the Board of Directors of Ceelite Technologies, LLC. She was the President of Lee Medical, a medical device manufacturer based in Plainsboro, New Jersey, from 2004-13. She was Chief Financial Officer of InfuSystem, Inc. (NASDAQ:INFU) from 2005 to 2007. From 1993 to 2003, Ms. Enright was with Citigroup, most recently as a Managing Director in its Equity Capital Markets group. While at Citigroup, Ms. Enright was Chairperson of the firm's Institutional Investors' Committee, responsible for screening and approving the firm's participation in equity underwritings and a member of the Citigroup Global Equity Commitment Committee, responsible for reviewing and approving the firm's underwritings. From 1989 until 1993, Ms. Enright was an attorney with Wachtell, Lipton, Rosen & Katz in the firm's New York office. Ms. Enright received her A.B. from the Woodrow Wilson School of Public and International Affairs at Princeton University and J.D. from the University of Chicago Law School.
STUART M. ESSIG, Ph.D., currently serves as managing director of his family office, Prettybrook Partners LLC, investing in medical technology companies. Prettybrook has approximately 25 active investments in a variety of companies, typically as a co-investor with institutional private equity.
Dr. Essig has been Integra LifeSciences Corporation's (NASDAQ:IART) Chairman of the Board of Directors since 2012 and a Director since he joined Integra in 1997. He served as the company's Chief Executive Officer from 1997 to 2012, building Integra into a global surgical products leader. During Stuart's more than 25-year tenure with the company, Integra has grown revenues from approximately $15 million to over $1.5 billion and its market capitalization from approximately $100 million to an aggregate valuation of more than $6.0 billion. Share price during his tenure has increased from approximately $6 to over $115 on a split-adjusted basis.
Before joining Integra, Dr. Essig was managing director of the medical technology practice at Goldman, Sachs & Co. He had ten years of broad healthcare experience at Goldman Sachs, serving as a senior merger and acquisitions advisor to a broad range of domestic and international medical technology, pharmaceutical and biotechnology clients.
Dr. Essig has chaired audit, compensation, finance and nominating and governance committees, served as lead director, and participated in CEO succession processes, on the boards of numerous public companies, ranging in size from several hundred million dollars to $50 billion in levered market capitalization.
In addition to Integra, Dr. Essig currently serves on the Board of Directors of IDEXX Laboratories, Inc. (NASDAQ:IDXX) and Orthofix (NASDAQ:OFIX). He serves as Chairman of the Board of Directors of venture backed Mission Bio Inc. He is also the Lead Director, and former Executive Chairman, of the Board of Directors of private-equity backed Breg, Inc., a premium provider of high-value sports medicine products and services that advance patient care in orthopedics, and also serves on the Board of Managers of Availity, LLC, the nation's largest real-time health information network.
He is a venture partner at Wellington Partners Advisory AG, a venture capital firm. He also serves as a senior advisor to TowerBrook Capital Partners. He previously served as a senior advisor to Water Street Healthcare Partners, and an executive-in-residence at Cardinal Partners. Dr. Essig was a founding investor member of Tigerlabs, a Princeton-based business accelerator.
Dr. Essig previously served on the Board of Directors of Seaspine Holdings (NASDAQ:SPNE), from 2014 to 2022, prior to its merger with Orthofix, and St. Jude Medical Corporation (NYSE:SJM) from 1999 to 2017, prior to its sale to Abbott Corporation. From 2013 until 2019 he served on the Board of Directors of Owens & Minor, Inc. (NYSE:OMI), from 2005 until 2008 he served on the Board of Directors of Zimmer Holdings, Inc. (NYSE:ZMH), and from 1998 to 2002, he served on the Board of Directors of Vital Signs, Inc. (NASDAQ:VITL). He also served on the executive committee, nominating and governance committee, and as treasurer of ADVAMED, the Advanced Medical Technology Association.
Dr. Essig is also involved in several non-profit charitable organizations, including from time to time serving on their boards. From 2012 to 2018, he served on the Board of Directors of Trenton-area non-profit, Isles, Inc. and since 2006 has served as a volunteer and fund raiser for the Children's Brain Tumor Foundation. He serves on the Leadership Council of the Princeton University School of Engineering and Applied Sciences, and previously served on the NACD Compensation Committee Chair Advisory Council.
Dr. Essig received an A.B. degree and graduated with magna cum laude and Phi Beta Kappa honors from the School of Public and International Affairs at Princeton University. He completed his M.B.A. and Ph.D. degrees in financial economics from the University of Chicago, Graduate School of Business.
Dr. Essig resides in Austin, TX.